The Current Bioinformatics Analytical Software Landscape By Charles Chang With the vast amount of biochemical data generated from experiments conducted by research laboratories around the globe, there is strong demand for software to analyse and manage the data effectively. Analytical software can be utilised to analyse virtually every single experiment,… Read More
Making the Most of Drug Discovery Data By Dr Nick Davies and Dr Tim Peakman Discovery scientists in most pharmaceutical companies are struggling with incompatible legacy systems, a growing volume of data and the imminent advent of a product model that will demand much more of them. Data-driven drug discovery… Read More
Gene Expression: Analysis and Drug R&D By Dr Ralph Sinibaldi It is clear that gene expression profiling systems have a role to play in many facets of drug discovery and development, but several questions remain. We take a look at the use of DNA microarray for gene expression or expression… Read More
Drug Discovery Spending - A Year In Review By Isaac Meek Drug In 2003, the research products market reported revenues of $23 billion, with a 7.5% growth rate over 2002. Although there are many consumers in this market, by far the greatest are drug discovery research groups. In recent history,… Read More
Role of image informatics in accelerating drug discovery and development By Robert Dunkle There is a new category of informatics that is proving itself essential to the acceleration of drug discovery and development. Image informatics is the systematic use of image data as a means to help interpret experiments and… Read More
Fewer drugs approved, more money spent - Where's the beef? By G. Steven Burrill Three years ago, when biotech was at its Wall Street heights, personalised medicine and its promise were on everyone's lips. Billions of dollars were being put to work to make targeted medicine a reality... and genomics… Read More
DNA repair inhibition to treat cancer and other serious illnesses By Professor Stephen P. Jackson and Cheryl L. Bishop The stability of an organism's genome is essential for healthy functioning and survival. The information content and integrity of the genome are so important that a range of maintenance and repair… Read More
By Dr Steven Bodovitz and Dr Scott D. Patterson The potential for parallel protein-based analyses to define a new era in diagnostics and drug development is generating considerable excitement in the field of proteomics. However, the discovery of differentially expressed proteins that correlate with a disease state or a drug… Read More
Biotechnology-based Orphan Drugs - Achievements and challenges By Dr Erik Tambuyzer For many patients suffering from rare diseases, there are simply no medicines available to treat their condition. With an estimated 20-30 million such patients in Europe alone, rare diseases collectively represent a significant unmet medical need. Individual disease groups,… Read More
Public Relations and the Drug Discovery Industry By Dr Richard Franklin The use of the Public Relations (PR) industry to promote all facets of the pharmaceutical industry is on the increase. We take a brief look at the various uses of PR and the sectors that are being promoted. Public… Read More
The Protein Biochip Content Problem By Dr Steven Bodovitz The protein biochip industry has a content problem that is not only slowing its development as a whole but possibly the development of the entire proteomics industry. In science, for a problem to have its own name, it needs to be… Read More
TRANSCRIPTOMICS - Realising the promise with a new era of drug discovery and diagnostics By Dr Bruce Seligmann The advent of modern genomics has provided new ways to link targets to diseases and validate these targets. The result is the potential for a new era of drug discovery transcriptomics or… Read More
Balancing Quantity and Quality in Drug Discovery By Eva-Lotta Allan There is a need to innovate in order to stay ahead, a need to maximise the value of the R&D engine by increasing the flow of novel drug candidates and yet, reduce the time to market. Does access to more… Read More
Secondary Screening Workstations - The emergence of compact turnkey solutions that work By Dr John Comley With the launch of new workstations focused on secondary screening applications not only are we witnessing the shrinkage of laboratory automation but we are seeing the emergence of true walk-away solutions, ie set up… Read More
The New Blockbuster Drugs - Healthcare packages for particular disease pathologies By Dr Nick Davies and Dr Steve Arlington With the cost of bringing a new drug to market now exceeding $800 million there is no doubt that the pharmaceutical industry has to fundamentally address the way in which it… Read More
Predictive chemoinformatics applications to the pharmaceutical industry By Dr Leslie J. Browne and Laurie L.Taylor While significant advances in chemoinformatics present tremendous opportunities to improve human health, the future of chemoinformatics in the pharmaceutical industry is not without significant challenges. Chemoinformatics is the result of collective advances in chemistry, biology,… Read More
